Alnuctamab for Refractory SLE (LATTE Study)

Part of paid clinical trials in New York, New York.

Sponsor
Icahn School of Medicine at Mount Sinai
Study ID
NCT07219563
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Alnuctamab — DRUG
    The study drug will be given as an injection under the skin. For the first 9 days after the CC-93269 injection, subjects will be staying in the hospital. The goal of this study is to determine the optimal dose of CC-93269 to be safely administered to participants.

Study Details

This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care treatments.

Key Dates

Start date
Mar 17, 2026
Status verified
Feb 2026
Primary completion
Dec 1, 2027
Completion
Dec 1, 2027

Study Design

Enrollment
21 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Participants with Lupus
    This study drug will be done by sentinel dosing (study drug given to a small number of participants to watch closely) before all the participants receive the study drug.

Primary Outcome Measure

Number of treatment emergent AEs [ Time Frame: 9 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Icahn School of Medicine at Mount SinaiNew YorkNew York10029
Chrisanna Dobrowolski, MD
[email protected]
212-241-1671
Chrisanna Dobrowolski (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

By condition
Lupus (SLE)
By specialty
RheumatologyAutoimmune disease
By research site
Icahn School of Medicine at Mount Sinai· New York, NY

Related Studies